الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
In this retrospective study, the files of 780 female patients with LABC presented to ACOD from Jan. 2003 to Dec. 2012 were reviewed with the aim of studying clinicopathological features and to evaluate treatment results.
The files of all patients included in this retrospective study were reviewed and data were collected including the following: complete history, clinical examination, histopathological data, types of surgery, chemotherapy received, radiotherapy, hormonal treatment, and treatment results as regards disease free survival and overall survival.
In the current study, the median age of patients was 50 years, 45.3% were premenopausal and 54.7% were postmenopausal and 4.2% had family history of breast cancer.
Left sided breast cancer was slightly more than the right sided breast cancer, and breast lump was the most common initial presentation in LABC patients.
Modified radical mastectomy was the most common type of surgery performed in our patients, 95.4% of patients had IDC, 69.4% had grade II and 91.2% had hormone receptor positive tumors.
Most of the patients had T2 or higher and had positive axillary LNs with 82.1% of the patients at stage IIIa.
In this study, 720 patients received adjuvant chemotherapy and only 60 patients received neoadjuvant chemotherapy with 32.7% of the patients showing recurrence (18% had local recurrence, while 14.7% had distant metastasis).
Lung followed by bone and brain were the most common sites of distant metastasis in our patients.
In this study, the most common chemotherapy regimen used was FAC in both adjuvant and neoadjuvant settings, whereas 591 patients received hormonal therapy (Tamoxifen, AIs).
Overall survival was higher in the patients who received neoadjuvant chemotherapy than those who received adjuvant chemotherapy; however, the difference was insignificant.
Antharcyclin based regimen achieved better OS in the neoadjuvant setting, while the difference was insignificant. Also, there was no significant difference among different hormonal agents correlated with the OS.
In this study, 768 patients received radiotherapy with the 45Gy/25f being the most common schedule used.
The 5 year DFS and OS was 65.8% and 72% respectively. There were factors affecting the DFS and OS including patients’ age, tumor grade, tumor size, hormonal receptor status and HER2 status, family history, and histopathological type of the tumor.
Febrile neutropenia, nausea, and vomiting were the most common side effects in the patients who received chemotherapy, while increased uterine thickness and DVT were found in the patients who received hormonal treatment. Skin pigmentation and dermatitis were found in the patients that received radiotherapy and lymphoedma was noted in 20% of the patients who underwent surgery.